The Prognosis of Patients After PCI：a Multi-center Study in China

Summary

Coronary artery disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular and cerebrovascular events (MACCE). At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Previous studies indicated that hsCRP ≥ 2mg / L was the definition standard of RIR in CAD in European and American people. In China, the impact of dynamic changes of hsCRP and other inflammatory factors on MACCE in PCI population remains unclear. Therefore, in this study, the investigators plan to recruit patients undergoing PCI, and observe the impact of hsCRP and other inflammatory factors on the prognosis of these patients during long term follow-up at 17 hospitals in China.

Conditions

• Inflammation

Sponsors & Collaborators

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• The First Affiliated Hospital of Zhengzhou University

  collaborator OTHER

• The First Affiliated Hospital of Xiamen University

  collaborator OTHER

• Shanxi Cardiovascular Hospital

  collaborator OTHER

• First People's Hospital of Xianyang

  collaborator OTHER

• Yichang Central People's Hospital

  collaborator OTHER

• Jingzhou Central Hospital

  collaborator OTHER

• The First Hospital of Wuhan

  collaborator UNKNOWN

• Wuhan Central Hospital

  collaborator OTHER

• Wuhan Fourth Hospital

  collaborator UNKNOWN

• Fifth Hospital in Wuhan

  collaborator UNKNOWN

• Chinese Academy of Medical Sciences, Fuwai Hospital

  collaborator OTHER

• Wuhan Asia Heart Hospital

  collaborator OTHER

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• Central Hospital of Enshi Tujia and Miao Autonomous Prefecture

  collaborator UNKNOWN

• Hubei University of Medicine

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  lead OTHER

Principal Investigators

• Xiang Cheng, Doctor · Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-11-01

Primary Completion

2027-11-01

Completion

2027-11-01

Countries

• China

Study Locations